State of California et al v. Teikoku Seiyaku Co., Ltd. et al

Filing 9

STIPULATED ORDER FOR ENTRY OF INJUNCTION. This action shall be dismissed with prejudice. Signed by Judge William H. Orrick on 02/12/2018. (jmdS, COURT STAFF) (Filed on 2/12/2018)

1
2
3
4
5
6
7

XAVIER BECERRA
Attorney General of California
KATHLEEN FOOTE
Senior Assistant Attorney General
ESTHER LA (SBN 160706)
Deputy Attorney General
455 Golden Gate Avenue, Suite 11000
San Francisco, CA 94102-7004
Telephone: [phone]
Fax: [phone]
E-mail: [e-mail]

11

CHERYL JOHNSON (SBN 66321)
PAMELA PHAM (SBN 235493)
Deputy Attorneys General
300 S. Spring Street, Suite 1700
Los Angeles, CA 90013
Telephone: [phone]
Fax: [phone]
E-mail: [e-mail];
[e-mail]

12

Attorneys for Plaintiff the State of California

13

[Additional Submitting Counsel on Signature Page]

8
9
10

14
15

IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF CALIFORNIA

16

SAN FRANCISCO DIVISION

17
18
19

STATE OF CALIFORNIA

Case No. 18-cv-675

20

STATE OF ALABAMA

21

STATE OF ARKANSAS

SETTLEMENT AGREEMENT AND
STIPULATED ORDER FOR ENTRY OF
INJUNCTION

22

STATE OF DELAWARE

23

DISTRICT OF COLUMBIA

24

STATE OF FLORIDA

25

STATE OF HAWAII

26

STATE OF IDAHO

27

STATE OF ILLINOIS

28

STATE OF INDIANA
1
Settlement Agreement And Stipulated Order For Entry Of Injunction (Case No. 18-cv-675_)

1

STATE OF IOWA

2

COMMONWEALTH OF KENTUCKY

3

STATE OF LOUISIANA

4

STATE OF MARYLAND

5

STATE OF MINNESOTA

6

STATE OF MISSISSIPPI

7

STATE OF NORTH DAKOTA

8

STATE OF OKLAHOMA

9

STATE OF OHIO

10

STATE OF RHODE ISLAND

11

STATE OF WASHINGTON

12

STATE OF WISCONSIN

13

COMMONWEALTH OF VIRGINIA

14
15

Plaintiffs,
v.

16
17

TEIKOKU SEIYAKU CO., LTD. and

18

TEIKOKU PHARMA USA, INC.

19

Defendants.

20
21

This Settlement Agreement and Stipulated Order for Entry of Injunction (ASO) is made and

22

entered into this 31st day of January, 2018, by and between the States of States of California,

23

Alabama, Arkansas, Delaware, Hawaii, Florida, Idaho, Illinois, Indiana, Iowa, Kentucky,

24

Louisiana, Maryland, Minnesota, Mississippi, North Dakota, Oklahoma, Ohio, Rhode Island,

25

Virginia, Washington, and Wisconsin, and the District of Columbia through their respective

26

Attorneys General acting in their law enforcement and sovereign capacities (the “States”), on the

27

one hand, and Teikoku Pharma USA, Inc. (TPU) and Teikoku Seiyaku Co., Ltd. (TSC)

28
2
Settlement Agreement And Stipulated Order For Entry Of Injunction (Case No. 18-cv-675_)

1

(hereinafter together “Teikoku”), on the other (collectively “Parties”). Any State electing to join

2

the ASO shall do so by executing a signature page that shall be annexed to this ASO.

3
4
5
6
7

WHEREAS, TSC manufactures a five-percent lidocaine patch product sold under the
brand name Lidoderm® in Japan, which it sells to its wholly owned subsidiary TPU;
WHEREAS, TPU is the owner of the New Drug Approval for Lidoderm® and TPU sells
Lidoderm® in the United States to Endo Pharmaceuticals;
WHEREAS, on May 28, 2012, Teikoku entered into a Settlement and License Agreement

8

with Endo Pharmaceuticals, Inc. and Watson Laboratories, Inc., which agreement settled

9

litigation captioned Endo Pharmaceuticals Inc., et al. v. Watson Laboratories, Inc., Civil Action

10

No. 1:10-cv-l38-GMS and Endo Pharmaceuticals Inc. v. Watson Laboratories, Inc., Civil Action

11

No. ll-cv-S75-GMS (the “Lidoderm Settlement and License Agreement”);

12

WHEREAS, the States contend that the Lidoderm Settlement and License Agreement

13

delayed and foreclosed competition from generic equivalents of Lidoderm® for a period of time

14

in violation of federal and state antitrust and consumer protection laws;

15
16
17

WHEREAS, the States initiated an investigation of Teikoku with respect to the above
alleged actions;
WHEREAS, Teikoku deny that they have engaged in any wrongful or unlawful conduct

18

and contend that they have, at all times, operated within the law and within industry standard

19

practices;

20
21
22
23
24

WHEREAS, the Parties have agreed to resolve any claims arising from the States’
investigation through this ASO;
WHEREAS, nothing in this ASO will be construed as a finding or admission of any
violation of law on the part of Teikoku;
WHEREAS, Teikoku have consented to this ASO and will comply with the provisions of

25

this ASO pending entry by the Court of the Stipulated Order for Entry of Injunction per the terms

26

of this ASO; and

27
28
3
Settlement Agreement And Stipulated Order For Entry Of Injunction (Case No. 18-cv-675_)

1

WHEREAS, the States contend that the entry of this ASO is in the public interest;

2

THEREFORE, IT IS on this 31st day of January, 2018 AGREED, as follows:
I.

3

DEFINITIONS

4

For purposes of this ASO, the following definitions apply:

5

1. “States” means the Attorneys General of the states of States of California, Alabama,

6

Arkansas, Delaware, Hawaii, Florida, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana,

7

Maryland, Minnesota, Mississippi, North Dakota, Oklahoma, Ohio, Rhode Island, Virginia,

8

Washington, and Wisconsin, and the District of Columbia.

9

2. “Teikoku” means Teikoku Pharma USA, Inc. and Teikoku Seiyaku Co., Ltd.

10

collectively, and their respective predecessors, affiliates, parent, and assigns, any joint venture,

11

subsidiary, division, group, or affiliate controlled directly or indirectly, currently or in the future,

12

by Teikoku, their successors and assigns, including successors in interest through bankruptcy,

13

merger, acquisition or otherwise, and the respective directors, officers, employees, agents, and

14

representatives acting on behalf of each.

15

3. “505(b)(2) Application” means an application filed with the United States Food and Drug

16

Administration pursuant to Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, 21

17

U.S.C.§ 355(b)(2).

18

4. “ANDA” means an Abbreviated New Drug Application filed with the United States Food

19

and Drug Administration pursuant to Section 505(j) of the Federal Food, Drug and Cosmetic Act,

20

21 U.S.C. § 355(j).

21

5. “Authorized Generic” or “AG” means a Drug Product that is manufactured pursuant to

22

an NDA and marketed, sold, or distributed in the United States under a name other than the

23

proprietary name identified in the NDA, or by the NDA Holder or a party at the direction or

24

consent of the NDA Holder.

25

6. “Brand/Generic Settlement” means any agreement or understanding that resolves, settles

26

or results in termination of a Patent Claim that has been threatened or made by or against an NDA

27

Holder with respect to any Patent alleged to cover any Drug Product, whether said Claim has

28
4
Settlement Agreement And Stipulated Order For Entry Of Injunction (Case No. 18-cv-675_)

1

been filed in a court or in the Patent & Trademark Office or before the Patent Trademark &

2

Appeals Board.

3
4

7. “Brand/Generic Settlement Agreement” means a written agreement that resolves, settles,
precedes or follows by up to 30 days the termination of a Patent Claim.

5

8. “Branded Subject Drug Product” means a Subject Drug Product marketed, sold, or

6

distributed in the United States under the proprietary name identified in the NDA for the Subject

7

Drug Product.

8

9. “Commerce” has the same definition as it has in 15 U.S.C. § § 12, 44.

9

10. “Control” or “Controlled” means the holding of more than fifty percent (50%) of the

10
11
12
13

common voting stock or ordinary shares in, or the right to appoint more than fifty percent
(50%) of the directors of, or any other arrangement resulting in the right to direct the
management of the said corporation, company, partnership, joint venture, or entity.
11. “Drug Product” means a finished dosage form (e.g., tablet, capsule, solution, or patch),

14

as defined in 21 C.F.R. § 3l4.3(b), that contains a drug substance, generally, but not necessarily,

15

in association with one or more other ingredients.

16

12. “Investigation” means the investigation conducted by the States.

17

13. “Generic Filer” means a party to a Brand/Generic Settlement who controls an ANDA or

18

505(b)(2) Application for the Subject Drug Product or has the exclusive right under such

19

ANDA or 505(b )(2) Application to distribute the Subject Drug Product.

20

14. “Generic Product” means a Drug Product manufactured and/or sold under an ANDA or

21

pursuant to a 505(b)(2) Application.

22

15. “Lidoderm Settlement and License Agreement” means the Settlement and License

23

Agreement entered into on or about May 28, 2012, by and between Endo Pharmaceuticals

24
25
26
27
28

Inc., Teikoku, and Watson Laboratories, Inc. relating to Lidoderm®.
16. “NDA” means a New Drug Application filed with the United States Food and Drug
Administration pursuant to Section 505(b) of the Federal Food, Drug and Cosmetic Act,
21 U.S.C. § 355(b), including all changes or supplements thereto that do not result in the
submission of a new NDA.
5
Settlement Agreement And Stipulated Order For Entry Of Injunction (Case No. 18-cv-675_)

17. “NDA Holder” means a party that controls the NDA for the Subject Drug Product or

1
2

has the exclusive right to distribute the Branded Subject Drug Product in the United States.
18. “No-AG Commitment” means any agreement with, or commitment or license to, a

3
4

Generic Filer that restricts, delays, transfers, imposes a condition precedent upon, or otherwise

5

interferes with the research, development, manufacture, regulatory approval, marketing or sale of

6

an Authorized Generic.

7

19. “Patent Claim” means any allegation threatened or included in a petition or complaint

8

filed with a court of law or with the United States Patent & Trademark Office or Patent Trial &

9

Appeal Board, that a Generic Product or other Drug Product may infringe any U.S. Patent held

10

by, or licensed to, an NDA Holder, or that any U.S. Patent held by the NDA Holder is invalid,

11

unenforceable or not infringed, or that any U.S. Patent held by a Generic Filer is invalid,

12

unenforceable or not infringed.
20. “Payment by the NDA Holder to the Generic Filer” means a transfer of any form of

13
14

value or consideration by the NDA Holder to the Generic Filer (including, but not limited to: a

15

No-AG Commitment; money; contracts for distribution, manufacturing, co-promotion, stand-by

16

manufacturing, co-development1; agreements about the dates of launch of the Subject Drug

17

Products or other drug products outside the United States; settlements of pre-existing lawsuits; or

18

other contracts for goods, or services) regardless of whether the Generic Filer purportedly

19

transfers value in return, where such transfer is either (i) implicitly or expressly contingent on

20

entering into a Brand/Generic Settlement Agreement, or (ii) agreed to or formulated in whole or

21

in part, during the 60 day period starting 30 days before executing a Brand/Generic Settlement

22

Agreement and ending 30 days after executing a Brand/Generic Settlement Agreement. The

23

following, however, are not Payments by the NDA Holder to the Generic Filer:

24
25
26
27
28

1

Contracts for distribution, manufacturing, co-promotion, stand-by manufacturing, codevelopment will not be considered Payments under this definition if they were contemplated,
executed and documented at least in part more than 30 days prior to the commencement of
discussion of the resolution of a Patent Claim or more than 30 days after the resolution of a Patent
Claim and are the result of an arms length transaction that is not implicitly or expressly
contingent on entering into a Brand/Generic Settlement Agreement.
6
Settlement Agreement And Stipulated Order For Entry Of Injunction (Case No. 18-cv-675_)

1

a. compensation for saved future litigation expenses of the Brand or Generic Filer that

2

Teikoku can prove was budgeted and forecast in writing in good faith at least four months prior to

3

the subject Brand/Generic Settlement Agreement, not to exceed a maximum limit which is

4

initially set at seven million dollars ($7,000,000) and shall be increased (or decreased) as of

5

January 1 of each year by an amount equal to the percentage increase (or decrease) from the

6

previous year in the annual average Producer Price Index for Legal Services (Series ld. PCU541

7

1--541 1--) published by the Bureau of Labor Statistics of the United States Department of Labor,

8

or its successor;

9

b. provisions in a Brand/Generic Settlement Agreement that provide only a date after which

10

a Generic Filer can begin selling, offering for sale, or distributing the Subject Drug Product on the

11

condition that Teikoku enters into no other agreements otherwise providing Payments to a

12

Generic Filer less than 30 days before or greater than 30 days after the resolution of the Patent

13

Claim;

14

c. continuation or renewal of a pre-existing agreement provided: (i) the preexisting

15

agreement was entered at least thirty (30) days before the relevant Brand/Generic Settlement

16

Agreement; (ii) the terms of the renewal or continuation, including the duration and the financial

17

terms, are substantially similar to those in the preexisting agreement; and (iii) entering the

18

continuation or renewal is not implicitly or expressly contingent on agreeing to a Brand/Generic

19

Settlement or termination of a Patent Claim.

20

d. provisions in a Brand/Generic Settlement Agreement that permit a Generic Filer to begin

21

selling, offering for sale, or distributing the Subject Drug Product once another drug company

22

begins selling, offering for sale, or distributing the Subject Drug Product.

23

21. “Subject Drug Product” means the Drug Product for which one or more Patent Claims

24

are settled under a Brand/Generic Settlement. For purposes of this Order, the Drug Product of the

25

NDA Holder and the Generic Filer to the same Brand/Generic Settlement shall be considered to

26

be the same Subject Drug Product.

27
28
7
Settlement Agreement And Stipulated Order For Entry Of Injunction (Case No. 18-cv-675_)

1

22. “U.S. Patent” means any patent issued by the United States Patent and Trademark

2

Office, including all divisions, reissues, continuations, continuations-in part, modifications, or

3

extensions thereof.

4

23. “States Enforcement Council” means counsel for the States of California, Minnesota,

5

Mississippi and any other State whose status as States Enforcement Council has been established

6

per this Agreement.
II.

7
8

A.

PROHIBITED AGREEMENTS

From the date Teikoku signs this ASO, Teikoku individually and collectively, are

9

prohibited from entering into any Brand/Generic Settlement that includes both: (1) Payment by

10

the NDA Holder to the Generic Filer; and (2) an agreement by the Generic Filer not to research,

11

develop, manufacture, market, or sell the Subject Drug Product or any other drug product for any

12

period of time.

13

B.

Nothing in this ASO shall preclude any State from challenging a future

14

Brand/Generic Agreement under otherwise applicable law if such future Brand/Generic

15

Agreement falls outside the scope of this ASO. Nothing in this ASO shall or can be utilized in

16

any litigation or manner outside of any enforcement action brought under this ASO.
III.

17
18

A.

ENFORCEMENT AUTHORITY

The States Enforcement Council shall consist initially of the Attorney General of the

19

State of California, the Attorney General of Louisiana, the Attorney General of Minnesota, the

20

Attorney General of Mississippi (the original States Enforcement Council). Any other State that

21

has provided Teikoku 30 days’ notice of its desire to serve as a member of the States Enforcement

22

Council shall become active members of the States Enforcement Council upon the expiration of

23

the 30-day notice period. The States that are party to this ASO shall have exclusive authority to

24

enforce this ASO as set forth herein, but only active members of the States Enforcement Council

25

shall have authority to implement the Reporting Requirements set forth under Section IV of this

26

ASO or the right to demand and receive Reports from Teikoku under this ASO.

27
28

B.

The States Enforcement Council shall have the exclusive authority to implement the

terms of this ASO by filing a complaint and request to enter the Stipulated Order for Injunctive
8
Settlement Agreement And Stipulated Order For Entry Of Injunction (Case No. 18-cv-675_)

1

Relief described herein. The exclusive forum to file such a complaint and request or in which to

2

file any complaint, petition or other action to enforce the terms of this ASO shall be the United

3

States District Court for the Northern District of California (the “Court”). The States

4

Enforcement Council shall also have the exclusive authority to seek such orders as are necessary

5

from the Court to enforce this Stipulated Order, provided, however, that the States Enforcement

6

Council will provide notice of an alleged violation and an opportunity to cure alleged violations

7

to Teikoku as set forth below. Notwithstanding the foregoing, any action by the Teikoku to cure

8

any such violation shall not be a defense to enforcement with respect to any knowing, willful or

9

systematic violations of this ASO.

10

C.

If any of the States Enforcement Council or any party State believes that a Teikoku

11

entity is not in compliance with the terms of this ASO, the States Enforcement Council shall give

12

Teikoku written notice of such alleged non-compliance. Teikoku shall have fifteen (15) working

13

days from the date of receipt to respond in writing to such notice unless the parties agree to a

14

longer period of time. If the States Enforcement Council is not satisfied with Teikoku’s response,

15

it shall notify Teikoku in writing, and Teikoku shall have thirty (30) calendar days from the date

16

of receipt of the States’ response to cure such non-compliance. If after such time, the States

17

Enforcement Council alleges that a Teikoku entity is still not in compliance, the States

18

Enforcement Council may seek enforcement, fees and costs thereof, and civil penalties as granted

19

by applicable state law. Nothing in this clause prohibits the States Enforcement Council from

20

pursuing immediate enforcement for potential noncompliance if delay would cause irreparable

21

harm or prevent the States Enforcement Council from adequately enforcing the ASO.

22

D.

The Parties agree that the exclusive venue for enforcing this ASO or any disputes that

23

arise out of the interpretation of this ASO or the entry of the Stipulated Order for Injunctive

24

Relief shall be the United States District Court for the Northern District of California (the

25

“Court”) and that no such action shall be brought in any other forum. The Parties agree to submit

26

to the jurisdiction of the Court to resolve such disputes and that the Court has the subject matter

27

to resolve them. The Parties further agree that venue to bring such action properly lies in the

28

Court.
9
Settlement Agreement And Stipulated Order For Entry Of Injunction (Case No. 18-cv-675_)

E.

1

To the extent the States Enforcement Council commences legal action to challenge a

2

Brand/Generic Settlement, any party State wishing to proceed as a member of the States

3

Enforcement Council as to that challenge must provide Teikoku with notice of its intention to do

4

so within 90 days of the commencement of such proceeding.

5
IV.

6
A.

7
8

REPORTING REQUIREMENTS

To determine and enforce compliance with this ASO, Teikoku shall submit to the

States Enforcement Council:

9

1) Copies of all agreements submitted to the Federal Trade Commission Bureau of

10

Competition and the Assistant Attorney General in charge of the Antitrust Division of the

11

Department of Justice pursuant to Section 1112 of the Medicare Prescription Drug, Improvement,

12

and Modernization Act of 2003 (the 2003 Act).
2) Copies of the written reports and additional documents required to be submitted to the

13
14

FTC under Section II of the FTC SO.
3) Along with each verified written report required under this section, Teikoku shall also

15
16

provide the States Enforcement Council a copy of any additional agreement with a party to a

17

Brand/Generic Settlement to which Teikoku is also a signatory if (i) the relevant Brand/Generic

18

Settlement Agreement includes an agreement by the Generic Filer not to research, develop,

19

manufacture, market or sell the Subject Drug Product for any period of time, and (ii) the relevant

20

additional agreement is entered within a year of executing the Brand/Generic Settlement

21

Agreement. For clarity, Teikoku need not submit such additional agreement to the extent such

22

agreement was submitted with a prior verified written report to the States Enforcement Council

23

pursuant to this ASO; this provision is intended to mirror the requirement set forth in the FTC

24

SO.

25

B.

Any reports or notices required under this ASO shall be submitted to each active

26

member of the States Enforcement Council. Specific address information for Teikoku and for

27

each current member of the States Enforcement Council and all States that are party to this ASO

28
10
Settlement Agreement And Stipulated Order For Entry Of Injunction (Case No. 18-cv-675_)

1

is attached hereto as Exhibit A. Teikoku may, at its option, provide notice to any State that is a

2

party to this ASO.

3

C.

No agreements, information or documents produced by Teikoku pursuant to this ASO

4

shall be divulged by any party State to any person not an authorized representative or retained

5

consultant or expert of any party State as set forth above, with the following exceptions:

6

1) in the course of a legal proceeding regarding enforcement or modification of this ASO

7

provided all parties to such a proceeding take reasonable steps to protect the confidentiality of

8

documents or information that they may reasonably understand Teikoku considers confidential;

9

2) as otherwise required by law for the purpose of securing compliance with this ASO

10

provided Teikoku is given notice and a reasonable opportunity to preserve the confidentiality of

11

documents that might otherwise be disclosed;

12

3) in a legal proceeding to which a party State is a party, or as otherwise required by law

13

(other than a grand jury proceeding), provided the party State shall reasonably attempt to preserve

14

such confidentiality by proceeding under any applicable protective order and utilizing sealing

15

procedures provided by law or court rule and by providing reasonable advance notice to Teikoku

16

(a minimum ten business days) before disclosing Teikoku’s confidential documents to a third

17

person.

18

4) to the Federal Trade Commission or the Department of Justice.

19

D.

Neither the terms of this ASO nor any reports or notices provided by Teikoku under

20

this ASO shall operate as a waiver of any future claims by any party. Further, any such reports or

21

notices provided by Teikoku to active members of the States Enforcement Council or to other

22

States that are parties to this ASO shall not be deemed to constitute actual or constructive notice

23

of any claims as to other states that have not received such reports or notices.
V.

24

CHANGE OF CORPORATE CONTROL

25

A.

Teikoku shall notify the States Enforcement Council within thirty (30) days of

26

1) Dissolution of Teikoku;

27

2) Any final acquisition, merger, or consolidation of Teikoku; or

28

3) Any other substantial change in Teikoku, including, but not limited to,
11
Settlement Agreement And Stipulated Order For Entry Of Injunction (Case No. 18-cv-675_)

1

assignment of a substantial portion of Teikoku’s assets, or the creation or dissolution of

2

subsidiaries, if such changes might affect Teikoku’s compliance with the obligations arising out

3

of this ASO.

4
5

B.

Teikoku shall submit any notice required under this paragraph to the States

Enforcement Council or, at its option, to any party States as set forth above.
VI.

6
7

A.

ACCESS TO INFORMATION

For the purpose of determining or securing compliance with this ASO, subject to and

8

without limiting any legally recognized privilege, and upon written request with reasonable

9

notice, Teikoku shall:

10

1) Timely respond to and cooperate with the States Enforcement Council’s reasonable

11

request for production of documents or information related to compliance to include unredacted

12

(except for privilege) internal written justifications and economic modeling;

13

2) Agree to accept service of process of any complaint filed hereunder provided it is filed

14

in the United States District Court for the Northern District of California and cooperation with

15

any subpoenas issued by the States Enforcement Council, and

16

3) Allow the States Enforcement Council to informally interview a reasonable number of

17

officers, directors, or employees of Teikoku who may have counsel present regarding such

18

matters.

19

B.

The States Enforcement Council will seek to coordinate any requests for information

20

under this Section with the FTC and Department of Justice, if involved, to the fullest extent

21

possible. The States Enforcement Council agrees to coordinate any and all requests and designate

22

one State to forward such requests from the States Enforcement Council.
VII. COOPERATION

23
24
25
26

A.

At the request of States Enforcement Council, Teikoku shall cooperate with the party

States in the Investigation as follows:
(1)

To the extent practical, Teikoku shall make its employees available in the United

27

States in person, by video conference, or by such other means as the Parties may agree to, for

28

such interviews and affidavits as reasonably required by the party States;
12
Settlement Agreement And Stipulated Order For Entry Of Injunction (Case No. 18-cv-675_)

1
2

(2) Upon request, Teikoku shall provide the last-known contact information for any former
employees;

3

(3) Teikoku shall produce at trial in person, by deposition, or by affidavit, whichever is

4

legally necessary, witnesses to testify as to the amount of their respective relevant sales and to

5

testify as to the genuineness, status as business records, and authenticity of documents;

6

(4) Teikoku will provide non-privileged evidence supporting the assertions made in the

7

July 30, 2015 presentation to the Federal Trade Commission Staff, which presentation was also

8

made to the States representatives on May 27, 2016.

9

(5) Notwithstanding anything in the foregoing, Teikoku will have no obligation to disclose

10

evidence provided to Teikoku pursuant to a joint defense agreement with Endo Pharmaceuticals,

11

Inc. and Actavis plc to the extent doing so would violate the terms of such agreement.

12

VIII. MONETARY RELIEF

13

The parties recognize that there is ongoing litigation between Teikoku and private class and

14

individual parties (the “Private Parties”) pending in the Northern District of California before

15

Judge Orrick concerning the claims that are the subject of this ASO. In the event that Teikoku

16

and the Private Parties ultimately agree to mediation or engage in settlement negotiations, the

17

States reserve the right to participate in said proceedings. The Parties agree, however, that a

18

recovery the States may receive from participating in such proceedings and the injunction

19

contemplated herein shall be the States’ exclusive remedy for any alleged violation by Teikoku

20

arising from the Lidoderm Settlement and License Agreement and that Teikoku does not

21

guarantee and shall have no obligation to ensure that the States Enforcement Council or the States

22

will be permitted to participate in such proceedings or that they will receive any monetary

23

recovery as any resolution between Teikoku and the Private Parties (“Private Resolution”).

24
25

IX.

RELEASED CLAIMS

In consideration of the injunctive provisions and the other commitments made by Teikoku

26

contained in this ASO, each State will be deemed to have fully, finally, and forever released

27

Teikoku and their officers, directors, employees, and attorneys (collectively “Releasees”) from

28

antitrust and consumer protection claims that were asserted or could have been asserted, by the
13
Settlement Agreement And Stipulated Order For Entry Of Injunction (Case No. 18-cv-675_)

1

State Attorneys General in his or her sovereign capacity as chief law enforcement officer of his or

2

her respective state, arising from the Lidoderm Settlement and License Agreement. This

3

agreement does not relate to or release criminal actions or any non-competition or non-consumer

4

protection claims regarding Lidoderm, including but not limited to those regarding Medicare or

5

Medicaid fraud, irregularities or false claims, off-label marketing, false advertising or product or

6

product liability claims.
X. EXPIRATION

7
8
9

This ASO will expire on the date that is the earlier of 20 years from the date Teikoku signs
this ASO or the expiration of the FTC SO.
XI. OTHER

10
11
12
13

A.

The terms of this ASO shall be binding on, and shall inure to the benefit of the Parties

and their successors.
B.

If any clause, provision, or section of this ASO shall, for any reason, be held illegal,

14

invalid, or unenforceable, such illegality, invalidity, or unenforceability shall not affect any other

15

clause, provision, or section of this ASO, and this ASO shall be construed and enforced as if such

16

illegal, invalid, or unenforceable clause, section, or other provision had not been contained herein.

17
18
19

XII. DISMISSAL AND COSTS
This action shall be dismissed with prejudice. Each party shall bear its own costs.
SO ORDERED this 12th day of February, 2018.

20
____________________________________
The Honorable William H. Orrick

21
22
23
24
25
26
27
28
14

Settlement Agreement And Stipulated Order For Entry Of Injunction (Case No. 18-cv-675_)